产时阿奇霉素对比安慰剂对新生儿脓毒症与死亡的影响:一项随机临床试验
这项双盲、安慰剂对照随机临床试验在西非冈比亚和布基纳法索的10个卫生机构纳入11983名分娩者,随机接受产时单次口服阿奇霉素2 g或安慰剂。主要终点新生儿脓毒症或死亡复合发生率两组相似(2.0% vs 1.9%;RD 0.09,95%CI -0.39至0.57),新生儿死亡和脓毒症分别比较亦无显著差异。阿奇霉素组新生儿皮肤感染(0.8% vs 1.7%;RD -0.90,95%CI -1.30至-0.49)和抗生素使用(6.2% vs 7.8%;RD -1.58,95%CI -2.49至-0.67)较低,产后乳腺炎和产褥热发生率也较低。作者结论认为产时口服阿奇霉素未减少新生儿脓毒症或死亡,不推荐常规引入。
要点
- 产时单次口服阿奇霉素2 g组与安慰剂组新生儿脓毒症或死亡复合终点发生率相似:2.0%(115/5889)vs 1.9%(110/5894),RD 0.09(95%CI -0.39至0.57)。
- 新生儿死亡率两组均为0.8%,RD 0.04(95%CI -0.27至0.35);新生儿脓毒症发生率均为1.3%,RD 0.02(95%CI -0.38至0.43)。
- 阿奇霉素组新生儿皮肤感染发生率低于安慰剂组:0.8% vs 1.7%,RD -0.90(95%CI -1.30至-0.49)。
- 阿奇霉素组新生儿4周随访期间抗生素使用率低于安慰剂组:6.2% vs 7.8%,RD -1.58(95%CI -2.49至-0.67)。
- 阿奇霉素组产后乳腺炎(0.3% vs 0.5%;RD -0.24,95%CI -0.47至-0.01)和产褥热(0.1% vs 0.3%;RD -0.19,95%CI -0.36至-0.01)发生率较低。
适用人群与场景
- 西非冈比亚和布基纳法索10个卫生机构中分娩的父母及其婴儿,2017年10月至2021年5月期间纳入。
- 分娩者中位年龄29.9岁。
处置流程与药物剂量
- 产时单次口服阿奇霉素2 g(随机1:1分配至阿奇霉素或安慰剂)。
研究设计与关键结果
- 研究类型:双盲、安慰剂对照随机临床试验,纳入11983名分娩者,来自10个卫生机构。
- 主要终点(新生儿脓毒症或死亡复合终点):阿奇霉素组2.0%(115/5889)vs 安慰剂组1.9%(110/5894),RD 0.09(95%CI -0.39至0.57)。
- 新生儿死亡:阿奇霉素组0.8% vs 安慰剂组0.8%,RD 0.04(95%CI -0.27至0.35)。
- 新生儿脓毒症:阿奇霉素组1.3% vs 安慰剂组1.3%,RD 0.02(95%CI -0.38至0.43)。
- 新生儿皮肤感染:阿奇霉素组0.8% vs 安慰剂组1.7%,RD -0.90(95%CI -1.30至-0.49)。
- 新生儿抗生素使用:阿奇霉素组6.2% vs 安慰剂组7.8%,RD -1.58(95%CI -2.49至-0.67)。
- 产后乳腺炎:阿奇霉素组0.3% vs 安慰剂组0.5%,RD -0.24(95%CI -0.47至-0.01)。
- 产褥热:阿奇霉素组0.1% vs 安慰剂组0.3%,RD -0.19(95%CI -0.36至-0.01)。
证据类型、等级与局限
- 证据类型:随机临床试验(双盲、安慰剂对照)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为产时口服阿奇霉素未减少新生儿脓毒症或死亡,这些结果不支持为此目的常规引入产时口服阿奇霉素。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT03199547
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Neonatal sepsis is a leading cause of neonatal mortality. New interventions are needed to decrease neonatal sepsis and mortality in regions with highest burden.
OBJECTIVE: To evaluate the efficacy of intrapartum azithromycin to reduce neonatal sepsis or mortality, as well as neonatal and maternal infections.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, randomized clinical trial enrolled and followed up birthing parents and their infants at 10 health facilities in The Gambia and Burkina Faso, West Africa, between October 2017 and May 2021.
INTERVENTIONS: Participants were assigned at random to receive oral azithromycin (2 g) or placebo (ratio 1:1) during labor.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of neonatal sepsis or mortality, with the former defined based on microbiologic or clinical criteria. Secondary outcomes were neonatal infections (skin, umbilical, eye and ear infections), malaria, and fever; postpartum infections (puerperal sepsis, mastitis), fever, and malaria; and use of antibiotics during 4-week follow-up.
RESULTS: The trial randomized 11 983 persons in labor (median age, 29.9 years). Overall, 225 newborns (1.9% of 11 783 live births) met the primary end point. The incidence of neonatal mortality or sepsis was similar in the azithromycin and placebo groups (2.0% [115/5889] vs 1.9% [110/5894]; risk difference [RD], 0.09 [95% CI, -0.39 to 0.57]), as was the incidence of neonatal mortality (0.8% vs 0.8%; RD, 0.04 [95% CI, -0.27 to 0.35]) and neonatal sepsis (1.3% vs 1.3%; RD, 0.02 [95% CI, -0.38 to 0.43]). Newborns in the azithromycin group compared with the placebo group had lower incidence of skin infections (0.8% vs 1.7%; RD, -0.90 [95% CI, -1.30 to -0.49]) and need for antibiotics (6.2% vs 7.8%; RD, -1.58 [95% CI, -2.49 to -0.67]). Postpartum parents in the azithromycin group had lower incidence of mastitis (0.3% vs 0.5%; RD, -0.24 [95% CI, -0.47 to -0.01]) and puerperal fever (0.1% vs 0.3%; RD, -0.19 [95% CI, -0.36 to -0.01]).
CONCLUSIONS AND RELEVANCE: Azithromycin administered orally during labor did not reduce neonatal sepsis or mortality. These results do not support routine introduction of oral intrapartum azithromycin for this purpose.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03199547.
参考来源
- Roca A, Camara B, Bognini JD, et al. Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death: A Randomized Clinical Trial. JAMA. 2023. PMID: 36881034. doi:10.1001/jama.2022.24388
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。